NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of RxSight, Inc. (NASDAQ: RXST) between November 7, 2024 and July 8, 2025. RxSight describes itself as a "commercial-stage medical technology company, engaged in the research and development, manufacture, and sale of light adjustable intraocular lenses.†For more information, submit a form, email attorney Phillip Kim, or gi. ...

Core Points - A class action lawsuit has been filed against RxSight, Inc. for alleged securities fraud and unlawful business practices [2][4] - Investors have until September 22, 2025, to request appointment as Lead Plaintiff if they purchased RxSight securities during the Class Period [2] - RxSight reported significant declines in Light Delivery Device sales and overall revenue, leading to a lowered full-year guidance by approximately $42.5 million [4] Financial Performance - Preliminary second quarter 2025 results showed a decline in Light Delivery Device sales and light adjustable intraocular lenses utilization [4] - Following the financial report, RxSight's stock price dropped by $4.84 per share, or 37.84%, closing at $7.95 per share on July 9, 2025 [4] Legal Context - The lawsuit is being handled by Pomerantz LLP, a firm recognized for its expertise in corporate and securities class litigation [5] - The firm has a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [5]

Group 1 - A securities class action lawsuit has been filed against RxSight, Inc. on behalf of investors who purchased its securities [1] - The class period for the lawsuit is from November 7, 2024, to July 8, 2025, and it alleges securities fraud and unlawful business practices [6] - RxSight reported significant declines in sales of its Light Delivery Device and lower usage of light adjustable intraocular lenses, leading to an overall revenue shortfall [6] Group 2 - The company cut its full year 2025 guidance by approximately $42.5 million due to "adoption challenges" affecting sales [6] - Following the negative news, RxSight's stock price dropped by $4.84, a decrease of 37.84%, closing at $7.95 per share on July 9, 2025 [6] - The lead plaintiff deadline for the lawsuit is September 22, 2025, encouraging affected investors to contact the law firm for more information [6]

Core Viewpoint - A class action lawsuit has been filed against RxSight, Inc. concerning allegations of securities fraud and unlawful business practices [2][3]. Financial Performance - On July 8, 2025, RxSight reported preliminary second quarter 2025 financial results, indicating significant declines in Light Delivery Device (LDD) sales, light adjustable intraocular lenses utilization, and overall revenue [3]. - The company lowered its full year 2025 guidance by approximately $42.5 million at the midpoint [3]. - Following the announcement, RxSight's stock price fell by $4.84 per share, or 37.84%, closing at $7.95 per share on July 9, 2025 [3]. Legal Context - Investors who purchased or acquired RxSight securities during the Class Period have until September 22, 2025, to request appointment as Lead Plaintiff [2]. - The lawsuit is being handled by Pomerantz LLP, a firm recognized for its expertise in corporate, securities, and antitrust class litigation [4].